[Clinical application value of Huanglian Jiedu Pills in improving syndrome of excess heat and fire toxin based on phase Ⅱ clinical trial study on plasma ATP, 4-HNE, and ACTH levels]

What Was Tested

Researchers studied ACTH (Corticotropin) in this randomized controlled trial publication.

Enzyme-linked immunosorbent assay(ELISA) was used to determine and evaluate the levels of adenosine triphosphate(ATP), 4-hydroxynonenal(4-HNE), and adrenocorticotropic hormone(ACTH) in plasma of the two groups before and after administration and to predict their application value as clinical biomarkers.

Why It Was Studied

A randomized, double-blind, placebo-controlled, multi-center phase Ⅱ clinical trial design was used in this study to recruit subjects who were in line with the syndrome of excess heat and fire toxin, and were diagnosed as recurrent oral ulcers, gingivitis, and acute pharyngitis.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this ACTH (Corticotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received ACTH (Corticotropin).

The comparison arm used a placebo, so changes seen with ACTH (Corticotropin) could be set against what happens without it.

A total of 240 cases were included and randomly divided into a placebo group and a Huanglian Jiedu Pills group.

What Was Measured

Topics PubMed links to this paper include Adrenocorticotropic Hormone, Hot Temperature, Medicine, Chinese Traditional, Adenosine Triphosphate and Drugs, Chinese Herbal.

The authors tagged it with the keywords 4-hydroxynonenal, Huanglian Jiedu Pills, plasma and syndrome of excess heat and fire toxin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ACTH (Corticotropin).

The publication is from 2023 (Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica), a journal based in China.

More context: the ACTH (Corticotropin) compound page, all human trials.